Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness and eventual paralysis. Most patients face a grim prognosis, with 70% succumbing within three years of diagnosis. Our recent study analysed a proprietary dataset from an ALS cohort, revealing intriguing findings:
* Metabolic Clues: We observed a paradoxical association-a lipid profile linked to cardiovascular risk appeared to reduce ALS risk. Additionally, metabolic disorders were more prevalent in ALS cases than in controls.
* Geographical Considerations: To validate our results, we’ll compare them with broader datasets, including UK Biobank data. Our proprietary dataset, derived from the US population, necessitates broader geographical representation.
* Predicting ALS Progression: Time matters in ALS progression. We aim to develop machine learning methods to detect pre-symptomatic metabolic changes. Early detection could revolutionize ALS management.
* In-House and UK Biobank Data: Our focus includes ~11,500 ALS patients and a matched control group. We’ll analyse lab observations and blood biomarkers, comparing results with UK Biobank cohorts.
* Method Two: Our innovative machine learning techniques will explore temporal aspects of patient data, considering disease progression acceleration.
Impact and Benefits:
* Public Awareness: Our research will raise awareness of early ALS risk factors, empowering individuals to seek timely intervention.
* Practitioner Insights: Healthcare professionals can proactively identify at-risk patients, potentially improving outcomes.
* Scientific Advancements: Novel biomarkers may guide treatment decisions and drug development.
* Personalized Health Monitoring: High-risk individuals can monitor their metabolic profiles for early signs.
In summary, this project bridges research and practical applications, aiming to transform ALS care.